Published in:
01-06-2011 | Original Article
Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1
Authors:
Toru Aoyama, Takaki Yoshikawa, Takafumi Watanabe, Tsutomu Hayashi, Takashi Ogata, Haruhiko Cho, Akira Tsuburaya
Published in:
Gastric Cancer
|
Issue 2/2011
Login to get access
Abstract
Background
Some patients experience a recurrence of cancer even after curative D2 gastrectomy followed by adjuvant S-1 chemotherapy. The objective of this retrospective study was to clarify the survival and prognosticators in these patients.
Methods
The study selected patients who underwent curative D2 surgery, were diagnosed with stage II, IIIA, or IIIB cancer, received adjuvant S-1 for more than 4 weeks, and experienced recurrence confirmed by an imaging study.
Results
A total of 34 patients were evaluated. The median overall survival (OS) was significantly longer in the 26 patients who received palliative chemotherapy than that in the 8 who did not (8.5 vs. 2.5 months, P = 0.002). Only 1 patient received S-1, 21 received taxane-containing regimens, and 4 received irinotecan plus cisplatin as the first-line chemotherapy. Univariate and multivariate analyses showed that the histological type was only independent significant prognosticator.
Conclusions
These results suggested that the survival did not reach the level expected for first-line chemotherapy. The histological type was a significant prognosticator in patients who experienced recurrence after adjuvant S-1 therapy and thereafter received palliative chemotherapy.